These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

220 related items for PubMed ID: 27435444

  • 1. CT-P13 (Inflectra™, Remsima™) monitoring in patients with inflammatory bowel disease.
    Schulze K, Koppka N, Lutter F, Brandhorst G, Schreiber S, Helwig U.
    Biologicals; 2016 Sep; 44(5):463-6. PubMed ID: 27435444
    [Abstract] [Full Text] [Related]

  • 2. Comparative Stability Studies of Different Infliximab and Biosimilar CT-P13 Clinical Solutions by Combined Use of Physicochemical Analytical Techniques and Enzyme-Linked Immunosorbent Assay (ELISA).
    Hermosilla J, Sánchez-Martín R, Pérez-Robles R, Salmerón-García A, Casares S, Cabeza J, Cuadros-Rodríguez L, Navas N.
    BioDrugs; 2019 Apr; 33(2):193-205. PubMed ID: 30875076
    [Abstract] [Full Text] [Related]

  • 3. Serum trough infliximab levels: A comparison of three different immunoassays for the monitoring of CT-P13 (infliximab) treatment in patients with inflammatory bowel disease.
    Malíčková K, Ďuricová D, Bortlík M, Hind'oš M, Machková N, Hrubá V, Lukáš M, Zima T, Lukáš M.
    Biologicals; 2016 Jan; 44(1):33-6. PubMed ID: 26603635
    [Abstract] [Full Text] [Related]

  • 4. A review of CT-P13: an infliximab biosimilar.
    McKeage K.
    BioDrugs; 2014 Jun; 28(3):313-21. PubMed ID: 24723086
    [Abstract] [Full Text] [Related]

  • 5. Progress in biosimilar monoclonal antibody development: the infliximab biosimilar CT-P13 in the treatment of rheumatic diseases.
    Braun J, Kudrin A.
    Immunotherapy; 2015 Jun; 7(2):73-87. PubMed ID: 25713985
    [Abstract] [Full Text] [Related]

  • 6. Can We Extrapolate Data from One Immune-Mediated Inflammatory Disease to Another One?
    Magro F, Coelho R, Peixoto A.
    Curr Med Chem; 2019 Jun; 26(2):248-258. PubMed ID: 30381062
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Efficacy and Safety of the Biosimilar Infliximab CT-P13 Treatment in Inflammatory Bowel Diseases: A Prospective, Multicentre, Nationwide Cohort.
    Gecse KB, Lovász BD, Farkas K, Banai J, Bene L, Gasztonyi B, Golovics PA, Kristóf T, Lakatos L, Csontos ÁA, Juhász M, Nagy F, Palatka K, Papp M, Patai Á, Lakner L, Salamon Á, Szamosi T, Szepes Z, Tóth GT, Vincze Á, Szalay B, Molnár T, Lakatos PL.
    J Crohns Colitis; 2016 Feb; 10(2):133-40. PubMed ID: 26661272
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Biosimilars in the therapy of inflammatory bowel diseases.
    Hlavaty T, Letkovsky J.
    Eur J Gastroenterol Hepatol; 2014 Jun; 26(6):581-7. PubMed ID: 24722561
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. [Biosimilars in inflammatory bowel disease].
    Siegmund B, Atreya R, Bokemeyer B, Kruis W, Mudter J, Sander C, Schreiber S, Reindl W, Zeissig S, Kucharzik T.
    Z Gastroenterol; 2016 Nov; 54(11):1217-1222. PubMed ID: 27711946
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Long-term Outcomes After Switching to CT-P13 in Pediatric-Onset Inflammatory Bowel Disease: A Single-Center Prospective Observational Study.
    Kang B, Lee Y, Lee K, Choi YO, Choe YH.
    Inflamm Bowel Dis; 2018 Feb 15; 24(3):607-616. PubMed ID: 29390113
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.